Oncoloxía médica

2018

1. A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain

   Clinical and Translational Oncology, Vol. 20, Núm. 8, pp. 1061-1071

2. ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer

   Oncotarget, Vol. 9, Núm. 24, pp. 16648-16664

3. ARole forCXCR4in peritonealandhematogenous ovarian cancer dissemination

   Molecular Cancer Therapeutics, Vol. 17, Núm. 2, pp. 532-543

4. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

   The Lancet Oncology, Vol. 19, Núm. 4, pp. 510-520

5. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study

   Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii611-viii612

6. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

   Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

7. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

   New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039

8. Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC

   Translational Lung Cancer Research, Vol. 7, Núm. 6, pp. 691-702

9. Challenges in lung cancer screening in Latin America

   Journal of Global Oncology, Vol. 2018, Núm. 4

10. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis

    Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567

11. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

12. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

    JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308

13. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473

14. Cyclosporine-loaded cross-linked inserts of sodium hyaluronan and hydroxypropyl-β-cyclodextrin for ocular administration

    Carbohydrate Polymers, Vol. 201, pp. 308-316

15. Dental management prior to radiation therapy in patients with head and neck cancer

    Indian Journal of Cancer, Vol. 55, Núm. 3, pp. 251-256

16. Development of microemulsions of suitable viscosity for cyclosporine skin delivery

    International Journal of Pharmaceutics, Vol. 545, Núm. 1-2, pp. 197-205

17. Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii225

18. Differential expression of snoRNAs in oral squamous cell carcinomas: new potential diagnostic markers

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 33, Núm. 1, pp. 424-427

19. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

    Clinical Microbiology and Infection, Vol. 24, pp. S41-S52

20. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

    Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264